Changes to the Oversight Structure for Research and Development, Business Development, and the Biomarker Business
First written in FY2017-Q2. 8 of 10 entries say "Advanced", first in FY2018-Q1. Latest entry: FY2024.
The whole theme swung hardest in 2026: 4 of 24 companies on the "Worse" side.
11 other companies' latest entry also says "Advanced".
- FY2024AdvancedAnnual report
「July 2024 Director, President and CFO of the Company」
The management structure changed in specific respects, including the appointment of a President and CFO in July 2024, the appointment of a Representative Director, President and CFO in September 2024, and the appointment of a new Head of the Business Administration Division as a director. - FY2021AdvancedAnnual report
「September 2020 Director and Head of the Corporate Administration Division of the Company (incumbent)」
The filing stated that Ohata (大畑) became a Director and Head of the Corporate Administration Division in September 2020. - FY2019AdvancedAnnual report
「September 2019 Director and Chairman of the Company (incumbent) September 2019 Representative Director and President of the Company (incumbent)」
As of the filing date, the officer structure had changed, with Kanno Ryuji (菅野 隆二) becoming Chairman and Hashizume Katsuhito (橋爪 克仁) becoming Representative Director and President. - FY2019-Q3AdvancedAnnual report
「Representative Director, President, Executive Officer, and President of the Metabolomics Business Company Kanno Ryuji (菅野 隆二) 23 November 2018 Director, Executive Officer, and President of the Biomarker Business Company Hashizume Katsuhito (橋爪 克仁) 23 November 2018」
The filing stated the officer structure effective 23 November 2018, including Kanno Ryuji (菅野 隆二) becoming President of the Metabolomics Business Company and Hashizume Katsuhito (橋爪 克仁) becoming President of the Biomarker Business Company. - FY2019-Q2AdvancedAnnual report
「Director and Executive Officer of the Company, President of the Biomarker Business Company (incumbent) Representative Director and President of HMTバイオメディカル株式会社 (incumbent)」
The filing stated that Hashizume Katsuhito (橋爪 克仁) became President of the Biomarker Business Company and Representative Director and President of HMTバイオメディカル株式会社 in December 2018. - FY2018-Q4AdvancedAnnual report
「Representative Director, President, Executive Officer, and President of the Metabolome Analysis Business Company Representative Director, President Kanno Ryuji (菅野 隆二) 1 July 2018 Director, Executive Officer, President of the Biomarker Business Company, and Head of the Research and Development Division Director, Head of the Research and Development Division, and responsible for the Biomarker Business Ohashi Yoshiaki (大橋 由明) 1 July 2018」
Effective 1 July 2018, the filing stated changes in titles and areas of responsibility for the Metabolome Analysis Business and Biomarker Business, including the introduction of a company president structure. - FY2018-Q2AdvancedAnnual report
「Retiring officer Director attached to the President Miyazaki Toshiyasu (宮崎 年恭) 31 December 2017 Director, HMTバイオメディカル株式会社」
The filing stated that Miyazaki Toshiyasu (宮崎 年恭) would retire effective 31 December 2017, following a change in title on 1 October 2017. - FY2018-Q1AdvancedAnnual report
「Director, Head of Research Division, and responsible for the Biomarker Business and Technology Development Division Director, Head of Research Division, and Head of the Business Development Office Ohashi Yoshiaki (大橋 由明) 1 October 2017」
Effective 1 October 2017, responsibility changed from the Business Development Office to the Biomarker Business and Technology Development Division for Ohashi Yoshiaki (大橋 由明). The changes in titles of officers on the biomarker business side, including appointments as presidents of subsidiaries, were also stated. - FY2017RestatedAnnual report
「Director, Head of Research Division and Head of Business Development Office」
The existing responsibility structure covering the Research Division, Business Development Office, biomarker business and Technology Development Division remains in place. - FY2017-Q2First statedAnnual report
「Director, Head of Research Division and Head of Business Development Office Director, Head of R&D Division and Head of Basic Metabolomics Research Department and Head of Business Development Office Ohashi Yoshiaki (大橋 由明) 1 July 2016 Director, Biomarker Business and responsibility for Technology Development Division Director, responsibility for Biomarker Business Miyazaki Toshiyasu (宮崎 年恭) 1 July 2016」
Effective 1 July 2016, the positions and areas of responsibility of the directors overseeing R&D, business development and the biomarker business changed.